Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,754)	$ (19,375)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	438	338
Amortization of intangible assets	121	242
Amortization of prepaid maintenance	18
Impairment charge for intangible assets	625
Stock-based compensation	1,479	1,630
Loss on sale of BioTime shares		309
Dividend income from AgeX Therapeutics common stock received as a dividend-in-kind	(96)
Unrealized loss on marketable equity securities	427
Warrants issued to certain shareholders as inducement to exercise of warrants		4,074
Amortization of debt issuance costs	77	83
Other	23
Changes in operating assets and liabilities:
Amount due to BioTime and affiliates	2	(753)
Prepaid expenses and other current assets	(11)	115
Accounts payable and accrued liabilities;	1,002	(48)
Net cash used in operating activities	(11,649)	(13,385)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net proceeds from sale of BioTime shares		934
Purchase of equipment	(31)	(91)
Net cash provided by (used in) investing activities	(31)	843
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	58	610
Proceeds from exercise of warrants		7,774
Proceeds from sale of common shares	10,000
Financing costs to issue common shares	(65)
Proceeds from sale of common shares and warrants	3,592
Financing costs to issue common shares and warrants	(290)
Proceeds from issuance of loan payable, net of financing costs		1,982
Repayment of loan payable	(800)	(133)
Repayment of capital lease obligation	(381)	(265)
Net cash provided by financing activities	12,114	9,968
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	434	(2,574)
CASH AND CASH EQUIVALENTS:
At beginning of the year	7,600	10,174
At end of the year	8,034	7,600
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	142	130
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Equipment purchased under capital leases	209	381
Debt issuance costs		$ 196